Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,612.00
Bid: 1,582.00
Ask: 1,695.00
Change: 0.00 (0.00%)
Spread: 113.00 (7.143%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,612.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Tech shines but tepid trade elsewhere

Wed, 26th Apr 2023 17:03

(Alliance News) - European equities closed lower on Wednesday, with lingering banking sector worries hurting sentiment, while tech stocks outperformed wider markets in New York after well-received earnings overnight.

In London, the FTSE 100 was hurt by share price falls for pharmaceutical stocks and building materials company CRH. Housebuilders and banking shares climbed, however.

The FTSE 100 index ended down 38.49 points, or 0.5%, at 7,852.64. The FTSE 250 fell just 7.42 points to 19,207.97. The AIM All-Share closed down 2.42 points, or 0.3%, at 821.84.

The Cboe UK 100 ended down 0.6% at 785.31, the Cboe UK 250, however, added 0.2% at 16,842.98. The Cboe Small Companies lost 0.2% at 13,293.67.

Stocks in New York were mixed on Wednesday. The Dow Jones Industrial Average was down 0.1%, while the S&P 500 index was up 0.3%, and the Nasdaq Composite surged 1.2%.

The tech-focused Nasdaq was an outlier in an otherwise tepid day for major indices.

Helping to boost the Nasdaq was a 7.8% share price rise for Microsoft.

It reported late Tuesday increased revenue and earnings in its financial third quarter, boosted by solid growth in its cloud division.

However, it received a blow on Wednesday after the UK's antitrust watchdog prevented its deal to acquire video game maker Activision Blizzard. Activision was down 11% in New York.

Microsoft said it would appeal the decision, and said the Competition & Markets Authority's decision reflects a "flawed understanding of this market and the way relevant cloud technology actually works".

The CMA said deal was blocked to "protect innovation and choice in cloud gaming".

In European equities on Wednesday, the CAC 40 in Paris closed down 0.9%, while the DAX 40 in Frankfurt ended down 0.5%.

"For today, the luxury sector appears to be seeing some profit-taking with Kering lower along with LVMH, Hermes, and Burberry weighing on the wider market, helping to push the CAC 40 sharply lower.

The FTSE 100 is also under pressure with the weakness very much broad-based across various sectors, with defensives feeling the pressure along with cyclicals, with health care a particular drag," CMC Markets analyst Michael Hewson commented.

In Paris, LVMH and Hermes each lost 1.6% and Kering gave back 2.3%. The latter late Tuesday reported first-quarter sales growth, though the Gucci owner's progress fell well short from growth seen from its peers. In London, Burberry fell 1.9%.

GSK and AstraZeneca lost 4.0% and 3.9%. The former reported a slip in quarterly sales on Wednesday. Astra reports on Thursday.

GSK said its top-line shrunk by 3.3%, reflecting less Covid-19 solution sales compared to the previous year.

Also hurting the FTSE 100, CRH fell 3.3%. It backed its half-year outlook but noted a challenging environment in Europe.

The building materials company said that reported sales in the first quarter of 2023 were up 7% year-on-year.

However, the company expects a more challenging backdrop in Europe, driven by continued inflationary pressures and some slowdown in the new-build residential sector.

Reckitt fell 2.6%. The consumer goods firm reported that price hikes supported its first-quarter outturn, though volumes slid.

The company said volumes fell 4.5% on-year in the first quarter of 2023, though it logged price/mix improvements of 12%. Reckitt said total net revenue in the first quarter rose 14% year-on-year to GBP3.92 billion from GBP3.42 billion a year earlier, or 7.9% on a life-for-like basis.

Unilever fell 0.9% in a negative read across. It reports a first-quarter trading statement on Thursday.

Housebuilders were on the up, however, lifted by an encouraging update from Persimmon. Persimmon closed up 5.1%.

The housebuilder said it expects to reach the top end of its 2023 expectations, despite a drop in sales in the first quarter on an annual basis.

Numbers suggest that the housing market has picked up from the fourth quarter, however.

It reported net private sales per outlet of 0.62, down 37% from 0.98 a year ago, but up from 0.30 in the final quarter of 2022.

The firm noted that forward sales also dropped on a yearly basis to GBP1.7 billion, 30% less than GBP2.4 billion the year prior, but up compared to GBP1.0 billion in the final quarter of 2022.

Persimmon said it expects full-year new home completions at the top end of its 8,000-9,000 guidance, "if sales rates continue around the level seen year to date".

Crest Nicholson and Redrow climbed 7.0% and 4.5%, respectively, in a positive read-across.

Standard Chartered added 2.8% on improved first-quarter earnings, bolstered by rate hikes.

The Asia-focused bank reported pretax profit of USD1.81 billion, up 21% from USD1.49 billion year-on-year.

Operating income climbed 6.2% to USD4.56 billion from USD4.29 billion. This was helped by net interest income rising 13% year-on-year to USD2.01 billion from USD1.78 billion, as it benefited from rising interest rates.

In addition, the company said it plans to return "in excess" of USD5 billion to shareholders by 2024.

Shares in banking sector peer Barclays, which reports on Thursday, climbed 1.7%.

Elsewhere in London, Warpaint added 7.1%.

The cosmetics supplier, which owns W7 and Technic makeup brands, said pretax profit multiplied in 2022 to GBP7.7 million from GBP3.7 million in 2021, driven by a 28% increase in revenue to GBP64.1 million from GBP50.0 million.

Looking ahead, Warpaint said trading has remained strong so far in 2023. Revenue in the first quarter was GBP18.5 million, up 40% from GBP13.2 million a year before, while margin improved on the 2022 full-year result.

The pound was quoted at USD1.2472 late Wednesday afternoon in London, higher compared to USD1.2404 at the London equities close on Tuesday. The euro stood at USD1.1046, higher against USD1.0983. Against the yen, the dollar was trading at JPY133.54, lower compared to JPY133.98.

The dollar suffered as Federal Reserve tightening expectations eased, though a hike next week still looks likely.

Fed tightening expectations eased after poor results from First Republic Bank reminded markets of the stress being felt by some US regional banks.

According to the CME FedWatch tool, there is an 81% chance that the central bank lifts rates by 25 basis points to a range of 5.00%-5.25% on Wednesday next week. The Fed is expected to pause hikes thereafter.

Still to come on Wednesday are results from Facebook owner Meta Platforms. Online retailer Amazon and pharmaceutical firm Merck & Co report on Thursday.

Aside from updates from AstraZeneca, Barclays and Unilever, the UK corporate diary has annual results from grocer Sainsbury's and a trading statement from advertising company WPP on Thursday.

The economic calendar has a US gross domestic product reading at 1330 BST.

Brent oil was quoted at USD80.29 a barrel late Wednesday, down from USD80.52 late Tuesday. Gold was quoted at USD1,995.53 an ounce, up against USD1,987.63.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.